Kyntra Bio, Inc.
KYNB· Nasdaq
KYNBKyntra Bio, Inc.
Filed Feb 26, 2024 · 10-K · 57 days after period end · 0000950170-24-020161
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $34.37M | $16.54M | $65.00M |
| Net Income | -$56.23M | -$66.18M | -$134.08M | -$58.63M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Feb 26, 2024 · 57 d after period end
